STRO
ANALYST COVERAGE20 analysts
BUY
+63.3%upside to target
L $43.00
Med $50.00consensus
H $60.00
Buy
1890%
Hold
15%
Sell
15%
18 Buy (90%)1 Hold (5%)1 Sell (5%)
Full report →
PRICE
Prev Close
31.13
Open
30.62
Day Range30.01 – 32.36
30.01
32.36
52W Range6.70 – 43.85
6.70
43.85
64% of range
VOLUME & SIZE
Avg Volume
231.2K
FUNDAMENTALS
P/E Ratio
-1.9x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.29
Market-like
TECHNICAL
RSI (14)
53
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 116 days
Sep 15

STRO News

About

at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
William Newell
Jonathan Fawcett DPHIL MBBSVP & Head of Clinical Development
Devendra LuharSenior Vice President of Technical Operations
Jane ChungChief Executive Officer & Director
Kari E. LeetchSenior VP and Head of People & Culture
James R. SwartzFounder
David PaulingChief Administrative Officer & General Counsel
Gregory K. ChowChief Financial Officer
Regina ChengVice President & Controller
Hans-Peter GerberChief Scientific Officer
Edward C. AlbiniSecretary